Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
USFM Looking Good!!
Shure Seems That Way Take Care!!
In USFM@.007
BOCL .014 Just Watching.
The April fools 15th trick!! (must read) have been tracking 10 stocks which are approching near record bottom prices. Because of tax selling or gaining!! as we all know right now stocks are quick and for the bucks. These stocks are more then their one year low, which I am tracking and for your entertainment purposes only. I do not post all the stocks I play, but in the days ahead I
will post some of these stocks. Gotcha you!! april 15th, picks up by May 1st. Most of us know why? Take Care!! Be back some time!! Thank you (The Hunt for the Next 5-10 Bagger) God bless this board!!
HBDT closed out for 100% and moved on!!
And so it begins!! started in February!! read the UOMO board for that month!! and just sit back and watch the show!! (Hint) then go to the
ibox above here in (THE WAVE) read the very good article on (101 long but good) I will take my chances and add again at some point!! if this works out, I will tell you what tipped me off some time ago, and it was more then just a few things!! if not its my money I will have lost!! I post all my buys and sells in my posts on a stock when I decide to buy it, just to show I win and lose like everyone else, and can also hold on to a stock for quite a while if I feel it might come around at some time. Took a starter position on this one below .045 Out for now!! Take Care!!
ISPI Interesting!!
ISPI In At .063 Took a Starter Position!!
Closed out at .17 made little profit out for the day take care!!
TGEN .16 Over $4mil.cash No Debt Gap At .30 could be filled at some point. Reminds me of ADLS last year, take a look at their chart, kinda close to this one on the gap. got lucky and made 100% on it. TGEN delisted itself from the NASDAQ and went to the pinks to save expenses, and not to have a reverse split as a means
to regain compliance with the $1.00 share price. They have a pipeline of prducts, if they announce positive results on any of their ongoing trials or a deal with a major player it could move this one nicely. Targeted Genetics Corp. in on this one in the .15 range. One to put on your radar!!
Key Statistics Get Key Statistics for:
Data provided by Capital IQ, except where noted.
VALUATION MEASURES
Market Cap (intraday)5: 3.30M
Enterprise Value (18-Feb-10)3: -669.57K
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-10) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 0.29
Price/Book (mrq): 1.21
Enterprise Value/Revenue (ttm)3: -0.06
Enterprise Value/EBITDA (ttm)3: 0.337
FINANCIAL HIGHLIGHTS
Fiscal Year
Fiscal Year Ends: 31-Dec
Most Recent Quarter (mrq): 30-Sep-09
Profitability
Profit Margin (ttm): -41.05%
Operating Margin (ttm): -24.59%
Management Effectiveness
Return on Assets (ttm): -14.69%
Return on Equity (ttm): -96.18%
Income Statement
Revenue (ttm): 11.33M
Revenue Per Share (ttm): 0.555
Qtrly Revenue Growth (yoy): 113.00%
Gross Profit (ttm): 8.72M
EBITDA (ttm): -1.99M
Net Income Avl to Common (ttm): -4.65M
Diluted EPS (ttm): -0.23
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 3.97M
Total Cash Per Share (mrq): 0.192
Total Debt (mrq): 0
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 2.356
Book Value Per Share (mrq): 0.132
Cash Flow Statement
Operating Cash Flow (ttm): -5.36M
Levered Free Cash Flow (ttm): -4.07M
View Financials (provided by EDGAR Online):
Income Statement - Balance Sheet
Cash Flow
ADVERTISEMENT
TRADING INFORMATION
Stock Price History
Beta: N/A
52-Week Change3: -23.81%
S&P500 52-Week Change3: 39.46%
52-Week High (09-Sep-09)3: 0.60
52-Week Low (23-Mar-09)3: 0.06
50-Day Moving Average3: 0.21
200-Day Moving Average3: 0.26
Share Statistics
Average Volume (3 month)3: 428,105
Average Volume (10 day)3: 131,571
Shares Outstanding5: 20.65M
Float: 17.90M
% Held by Insiders1: 8.05%
% Held by Institutions1: 7.70%
Shares Short (as of 31-Dec-09)3: 373
Short Ratio (as of 31-Dec-09)3: 0
Short % of Float (as of 31-Dec-09)3: N/A
Shares Short (prior month)3: 2.82K
Dividends & Splits
Forward Annual Dividend Rate4: N/A
Forward Annual Dividend Yield4: N/A
Trailing Annual Dividend Rate3: N/A
Trailing Annual Dividend Yield3: NaN%
5 Year Average Dividend Yield4: N/A
Payout Ratio4: N/A
Dividend Date3: N/A
Ex-Dividend Date4: N/A
Last Split Factor (new per old)2: N/A
Last Split Date3:
Press Release Source: Targeted Genetics Corporation On Tuesday February 9, 2010, 6:00 am EST
SEATTLE--(BUSINESS WIRE)--Targeted Genetics Corporation (Pink Sheets:TGEN - News) (the “Company”) today announced that it has completed the technology transfer portion of the September 2009 asset sale transaction executed between the Company and Genzyme Corporation (“Genzyme”) and has received the full $7.0 million provided for in the asset purchase agreement. As previously announced, the Company received $3.5 million from Genzyme at the closing of the transaction and was eligible to receive up to an additional $3.5 million upon the achievement of seven technology transfer milestones. The Company completed all seven technology transfer milestones and received aggregate payments from Genzyme of $2.5 million in the fourth quarter of 2009 and $1.0 million in the first quarter of 2010 for a total of $3.5 million.
In addition, the Company reported today that it received a $750,000 milestone payment from Amsterdam Molecular Therapeutics B.V. (“AMT”). This milestone payment was received pursuant to a patent license agreement between the Company and AMT and was triggered by AMT’s filing for marketing approval of Glybera®, a product candidate for the treatment of lipoprotein lipase deficient patients. AMT announced the regulatory filing with the European Medicines Agency on January 11, 2010.
The Company estimates it finished 2009 with cash and cash equivalents of approximately $4.9 million. The Company intends over the next year to utilize its resources to support continued efforts to monetize certain assets, to realize value from milestone and royalty licensing relationships, and to support product development programs currently underway with commercial and academic partners. Accordingly, based on its current business plans the Company expects its net use of cash during 2010 will not exceed $2 million. The Company’s use of cash in 2010 could be greater if the Company decides to increase spending during the year on new or current programs or other operating activities.
Under the September 2009 asset purchase agreement, the Company sold manufacturing technologies and other adeno-associated viral (AAV) vector technology to Genzyme. Under the agreement, Genzyme agreed to pay up to $7 million for the assets and the successful transfer of the technology and also agreed to pay a portion of sublicensing revenue received during a specified timeframe and royalties on net product sales of products if Genzyme successfully commercializes products utilizing the acquired Targeted Genetics technology. The Company entered into a non-exclusive patent license agreement with AMT in 2006 which covers Glybera®. The license agreement provides for AMT to pay royalties on net product sales, milestone payments upon the achievement of certain product development targets and annual maintenance payments.
“As a result of our significant expense reduction efforts, resolution of liabilities and payments received from partners, the Company has a stable financial footing as we continue to work to maximize the value of existing assets and consider alternatives for advancing the Company,” said B.G. Susan Robinson, President and Chief Executive Officer.
About Targeted Genetics Corporation
Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative therapies for the prevention and treatment of diseases with significant unmet medical need. To learn more about Targeted Genetics, visit its website at www.targetedgenetics.com
PRODUCT DEVELOPMENT PIPELINE
Targeted Genetics Corporation is committed to the development and commercialization of innovative therapies for the prevention and treatment of diseases with significant unmet medical need. Our efforts focus on utilizing an Adeno-Associated Virus (AAV) technology platform to deliver therapeutic constructs that increase or decrease gene function. We hold AAV-based assets for therapeutic program efforts and control important intellectual property rights around AAV serotypes, certain therapeutic uses of AAV and intellectual property and know-how relevant to AAV manufacturing. In addition to certain early stage pre-clinical program development efforts, we are currently developing, through collaborations, product candidates in Leber’s congenital amaurosis (LCA), a form of blindness, heart failure and Huntington’s disease (HD), a neurological disease.
LCA:
Our leading product development efforts focus on the investigation of a clinical-stage AAV-based product candidate for treatment of Leber’s Congenital Amaurosis (LCA) – an ocular disease that leads to blindness due to the effects of a mutation of the RPE65 gene. Utilizing AAV vectors to deliver the RPE65 gene, this product candidate is currently under evaluation in subjects in a Phase 2 dose escalation clinical trial. It is anticipated that interim data will be available from this trial at several different points of time throughout 2010, and that final data will be complete by the end of 2010. This product candidate is being developed in collaboration with Robin Ali, Ph.D., at the University College London/Moorfields Eye Hospital.
Heart Failure:
Under license and manufacturing agreements, Celladon Corporation utilizes proprietary AAV vector technology from Targeted Genetics for the development of MYDICAR® – a genetically-targeted enzyme replacement therapy for advanced heart failure. MYDICAR is currently under evaluation in subjects in a Phase 1/2 clinical trial. We manufactured Celladon’s MYDICAR product candidate for phase 1, 2 and future phase 3 clinical studies. We have transferred technology to enable Celladon to manufacture MYDICAR in the future through contract manufacturing organizations or a commercial partner, and if the program progresses further through clinical studies and through the FDA approval process, we could receive significant milestone payments and royalties.
HD:
Preclinical studies focused on identifying a candidate to develop a therapeutic for the treatment of Huntington’s disease (HD) continue in the laboratory of Beverly Davidson, Ph.D., at the University of Iowa (UI). HD is an incurable neurodegenerative disorder that results from mutations to the gene that codes for the huntingtin protein. Based on preclinical data collected over the last year, scientists at UI are performing additional research efforts with the goal of identifying a product candidate to put on a development path. We have a licensing relationship with UI around certain intellectual property resulting from Dr. Davidson’s research efforts.
Inflammatory Arthritis:
In 2008 we completed a Phase 2 clinical trial of tgAAC94 for the treatment of inflammatory arthritis, which included 127 patients in a randomized placebo controlled trial. The trial data demonstrated that tgAAC94 was well tolerated and showed preliminary signs of efficacy, most notably a 30% decrease in patient-reported pain and functional scores. Based on our currently available resources, we will initiate additional clinical studies of tgAAC94 only with additional external funding from a development and commercialization partner.
HIV/AIDS Vaccines:
Preclinical development for the HIV/AIDS vaccine development project, which was funded by the National Institute of Allergy and Infectious Diseases, and under subcontract with Children’s Hospital of Philadelphia and Nationwide Children’s Hospital, has been completed. Our preclinical development and manufacturing of material for clinical trials under this contract is now complete as the program is entering into clinical trials which will be funded and managed by NIAID.
ALS:
We have discontinued preclinical development of a small-molecule-based product candidate to treat amyotrophic lateral sclerosis (ALS), which was under development with collaborator John Engelhardt, Ph.D., at the University of Iowa.
TGEN .16 Possible Double At Some Point If it fills the gap at .30 from here or from todays low .13 and then again it could go lower. (4 million) cash and then some to play with again to start over with a new game plan!! No debt!!
Targeted Genetics Corp. Was delisted from NASDAQ
Key Statistics Get Key Statistics for:
Data provided by Capital IQ, except where noted.
VALUATION MEASURES
Market Cap (intraday)5: 3.30M
Enterprise Value (17-Feb-10)3: -463.04K
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-10) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 0.31
Price/Book (mrq): 1.31
Enterprise Value/Revenue (ttm)3: -0.04
Enterprise Value/EBITDA (ttm)3: 0.233
FINANCIAL HIGHLIGHTS
Fiscal Year
Fiscal Year Ends: 31-Dec
Most Recent Quarter (mrq): 30-Sep-09
Profitability
Profit Margin (ttm): -41.05%
Operating Margin (ttm): -24.59%
Management Effectiveness
Return on Assets (ttm): -14.69%
Return on Equity (ttm): -96.18%
Income Statement
Revenue (ttm): 11.33M
Revenue Per Share (ttm): 0.555
Qtrly Revenue Growth (yoy): 113.00%
Gross Profit (ttm): 8.72M
EBITDA (ttm): -1.99M
Net Income Avl to Common (ttm): -4.65M
Diluted EPS (ttm): -0.23
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 3.97M
Total Cash Per Share (mrq): 0.192
Total Debt (mrq): 0
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 2.356
Book Value Per Share (mrq): 0.132
Cash Flow Statement
Operating Cash Flow (ttm): -5.36M
Levered Free Cash Flow (ttm): -4.07M
View Financials (provided by EDGAR Online):
Income Statement - Balance Sheet
Cash Flow
ADVERTISEMENT
TRADING INFORMATION
Stock Price History
Beta: N/A
52-Week Change3: -23.81%
S&P500 52-Week Change3: 39.46%
52-Week High (09-Sep-09)3: 0.60
52-Week Low (23-Mar-09)3: 0.06
50-Day Moving Average3: 0.21
200-Day Moving Average3: 0.26
Share Statistics
Average Volume (3 month)3: 428,105
Average Volume (10 day)3: 131,571
Shares Outstanding5: 20.65M
Float: 17.90M
% Held by Insiders1: 8.05%
% Held by Institutions1: 7.70%
Shares Short (as of 31-Dec-09)3: 373
Short Ratio (as of 31-Dec-09)3: 0
Short % of Float (as of 31-Dec-09)3: N/A
Shares Short (prior month)3: 2.82K
Dividends & Splits
Forward Annual Dividend Rate4: N/A
Forward Annual Dividend Yield4: N/A
Trailing Annual Dividend Rate3: N/A
Trailing Annual Dividend Yield3: NaN%
5 Year Average Dividend Yield4: N/A
Payout Ratio4: N/A
Dividend Date3: N/A
Ex-Dividend Date4: N/A
Last Split Factor (new per old)2: N/A
Last Split Date3:
Press Release Source: Targeted Genetics Corporation On Tuesday February 9, 2010, 6:00 am EST
SEATTLE--(BUSINESS WIRE)--Targeted Genetics Corporation (Pink Sheets:TGEN - News) (the “Company”) today announced that it has completed the technology transfer portion of the September 2009 asset sale transaction executed between the Company and Genzyme Corporation (“Genzyme”) and has received the full $7.0 million provided for in the asset purchase agreement. As previously announced, the Company received $3.5 million from Genzyme at the closing of the transaction and was eligible to receive up to an additional $3.5 million upon the achievement of seven technology transfer milestones. The Company completed all seven technology transfer milestones and received aggregate payments from Genzyme of $2.5 million in the fourth quarter of 2009 and $1.0 million in the first quarter of 2010 for a total of $3.5 million.
In addition, the Company reported today that it received a $750,000 milestone payment from Amsterdam Molecular Therapeutics B.V. (“AMT”). This milestone payment was received pursuant to a patent license agreement between the Company and AMT and was triggered by AMT’s filing for marketing approval of Glybera®, a product candidate for the treatment of lipoprotein lipase deficient patients. AMT announced the regulatory filing with the European Medicines Agency on January 11, 2010.
The Company estimates it finished 2009 with cash and cash equivalents of approximately $4.9 million. The Company intends over the next year to utilize its resources to support continued efforts to monetize certain assets, to realize value from milestone and royalty licensing relationships, and to support product development programs currently underway with commercial and academic partners. Accordingly, based on its current business plans the Company expects its net use of cash during 2010 will not exceed $2 million. The Company’s use of cash in 2010 could be greater if the Company decides to increase spending during the year on new or current programs or other operating activities.
Under the September 2009 asset purchase agreement, the Company sold manufacturing technologies and other adeno-associated viral (AAV) vector technology to Genzyme. Under the agreement, Genzyme agreed to pay up to $7 million for the assets and the successful transfer of the technology and also agreed to pay a portion of sublicensing revenue received during a specified timeframe and royalties on net product sales of products if Genzyme successfully commercializes products utilizing the acquired Targeted Genetics technology. The Company entered into a non-exclusive patent license agreement with AMT in 2006 which covers Glybera®. The license agreement provides for AMT to pay royalties on net product sales, milestone payments upon the achievement of certain product development targets and annual maintenance payments.
“As a result of our significant expense reduction efforts, resolution of liabilities and payments received from partners, the Company has a stable financial footing as we continue to work to maximize the value of existing assets and consider alternatives for advancing the Company,” said B.G. Susan Robinson, President and Chief Executive Officer
Stock Watch!! UOMO .032 Sound Crazy!! Canadian Stock!! Just might want to watch this one. On chart jaws opening up!! getting close!! to closing!! but not yet!! when they start to close means upward movement!! Hint!! AM!! what could these letters mean?? out for today!! take care!! and no!! I have not been drinking!!
Closed position today for small loss!! Take Care!!
Closed out position today!! had averaged down to .006 for my average, took a small loss take care and good luck!!
Added at .005 thats it for me averaging down!! Have a nice weekend and I wish us all the best!! take care!!
Looks like this might happen from my post on (The Hunt For The Next 5-10 Bagger) part of post is below. The tricky part is where it goes from there. Out for the weekend take care!!
Posted by: barn dog Date: Thursday, December 31, 2009 4:40:56 AM
In reply to: None Post #143319 of 175129
Stock To Watch!! MDGC .008 Still Think This one will do well in the coming New Year!! In on this one at .01 .0085 with buy orders in at lower prices which I think could test the .005 mark before hopefully, starting its next run which could be a 10 bagger from there
MDGC .0079 +14.49% Gear Stuck In Neutral Will be interesting to see what happens today.
MDGC another uptick interesting!!
MDGC .0072 Getting Close To Reversal Or Tease!! at some point or back down!! time will tell!!
Time Will Tell Take Care!! My Post On (The Hunt For The Next 5-10 Bagger) post # 143319 will tell you what I think might happen, and at what point I started buying. And if you read my last two buys in my recent posts, I averaged down some more. I post all my buys and sells in any stock I buy, that way if I win good for me!! if I lose oh well!! just my own guess only!! wishing us that do own this stock or anyone that might buy in the best!! That is what we all wish when we buy a stock!! Out for the rest of the day. Take Care!! God Bless You All!!
2 Stocks That Could Make a Nice Bounce!! at some point (IFUS) Impact Fusion Intl. .018 and (CLKZ) Clicker Inc. .0027 CLKZ seems to be a good buy around .0025 and under. IFUS is getting into the health and wellness area and seems to be a good buy at .02 and under. Looking for some nice possible bounces on these at some point. Just a couple of stocks to watch!!
MDGC added at .007
MDGC .0075 next week could be interesting!!
UOMO .04 Grammy Awards Sunday Night This Stock has been in a downtrend, and at some point could change. Looking for a possible 10 bagger for this year.
TORONTO, ONTARIO--(Marketwire - 01/28/10) - UOMO Media Inc. (OTC.BB:UOMO - News), a multi-channel entertainment company, announced today that producer and songwriter Christopher "Tricky" Stewart, has been nominated for Grammys for his work with Beyonce and Jamie Foxx.
"Redzone's work with Beyonce and Jamie Foxx has been recognized by their peers and fans," said Mr. Camara Alford, Chairman and CEO, UOMO Media. "Simply put, Tricky creates music that resonates with colleagues and audiences around the world. They had a stellar year in 2009 and 2010 will be no different."
Terius "The-Dream" Nash and "Tricky" Stewart of Redzone Entertainment are nominated for their work on Beyonce's smash album "I am... Sasha Fierce" including the hit single, "Single Ladies." In sum, Beyonce was nominated for Album of the year, Song of the Year, Best R&B Song, Best Female R&B Performance and Best Contemporary R&B Album.
The team at Redzone also produced and wrote for Jamie Foxx's Best Contemporary R&B nominated album "Intuition."
The 52nd Grammy Awards air on CBS on January 31. In 2010, Redzone Entertainment signed an exclusive international management agreement with UOMO Media Inc.
About Redzone Entertainment Inc.
Redzone Entertainment was founded by brothers Tricky Stewart, Mark E. Stewart, and Laney Stewart in 1995. Since then Redzone's discography has grown exponentially with collaborations with some of the most talented artists in the world, responsible for over 25 million records sold, producing acts such as Mariah Carey, Pink, Madonna, Whitney Houston, Justin Bieber, Snoop Dogg, Britney Spears, Celine Dion, Mary J. Blige, and Rihanna.
About UOMO Media Inc.
UOMO Media Inc. is a multi-channel entertainment company that acquires, produces, and manages intellectual media content. UOMO integrates existing and well-established revenue streams in recorded music, publishing, and talent management through its five operating divisions: UOMO Digital, UOMOLife (including AdUOMO), UOMO Recorded Music, UOMO Talent Management, and UOMO Publishing. For more details please visit www.uomomedia.com or www.uomolife.com
http://www.dailytimes.com.pk/default.asp?page=2010%5C01%5C30%5Cstory_30-1-2010_pg9_1
http://uomomedia.com/blank.html
MDGC added here at .0075 getting hammered!!
This Board Money Wise!! Is Full Of Bucks!! People you have to make your own choices, what will it be??
Dogs Picks!! Are You In A Hurry!! If so good luck!! If you want to get rich!! Fast!! Do not expect it from me!! This board is your chance to make it rich!! only on your choice only!! My picks take time!!
What Would Warren Buffett Do!! 2 Stocks That suck!! on the down trend. One or both of these could be a 1000% gainer. Sound crazy!!
Not really!! Details after midnight!! Buy when every one is fearfull!! Sell when everyone is greddy!! As for me I just post my buy and sells in all my posts. I enjoy playing the market and am in no hurry!! win or lose!! its how you play the game!! Take Care!!
What Would Warren Buffet Do? 2 Stocks That suck!! or would we say as warren says be greedy when every one is fearful!! Coming up after midnight. Possible bounce on one stock, 1000%
God Bless This Board!! And Take Care!!
Take Care Brick!! I Have A lot Of respect for you on this board!!
Brick!! MUTM Its Time Could Come!! You Could have hit a nice one
almost jumped in it today. Watching it closely my loss if I miss out on it. Just taking it easy and enjoying my free life, I do see a nice bounce at higher prices!! at some point!!
Bagger Board Doing Great!! Take Care!!
Interesting!! Time Will Tell!! Take Care!!
Interesting!! Time Will Tell!! Take Care!!
CLKZ getting nice volume!!
UGS Great Call.....Nice!
Sorry!! have not been watching it for a while, hope you do good on it. Out for the day take care!!
MDGC could get interesting this week !! Buzz Cloud picking up on this one. Possible .06 to .10 this year. Mediag3 Inc. (.0101)